Agenda
10:00 a.m. 鈥� 11:00 a.m.
Registration & Brunch
11:00 a.m. 鈥� 11:15 a.m.
Welcome Remarks
Julia Schueler, Head of In Vivo Operations - Oncotest, a Charles River company
11:15 a.m. 鈥� 12:00 p.m. Keynote Speaker
Advanced Image Analysis and Mathematical Modeling to Explore Spatial Patterns of the Inflammatory Tumor Microenvironment
Friedrich Feuerhake, MD, Associate Professor of Neuropathology, Attending Neuropathologist, Head of Digital Pathology Group - Hanover Medical School
12:00 noon 鈥� 12:35 p.m.
TLR9 Agonists for the Immunotherapy of Cancer
Manuel Schmidt, PhD, Director of Translational Research, Oncology & Immunotherapy - Mologen
12:35 p.m. 鈥� 12:55 p.m. Break
12:55 p.m. 鈥� 1:30 p.m.
Multi-Pronged Attack on Cancer by Stimulation of the Innate Immune Receptor RIG-I Leads to Systemic Anti-Tumor Immunity
Marcel Renn, PhD, Project Leader, Biology - Rigontec
1:30 p.m. 鈥� 2:05 p.m.
Catarina Brito, PhD, Research Associate, Head of BioAssay Development Laboratory - ITQB-UNL
2:05 p.m. - 2:40 p.m.
Tools for the Next Generation of Immunotherapy
Olaf Hardt, PhD, Senior Project Manager - Miltenyi Biotec
2:40 p.m. 鈥� 3:00 p.m. Break
3:00 p.m. 鈥� 3:35 p.m.
Costimulatory T-cell Engagement with the CD137/HER2 Bispecific PRS-343 Demonstrates that Safe and Efficient Targeting of Costimulatory Receptors Requires Bispecifics
Marlon Hinner, PhD Director, Immuno-Oncology - Pieris Pharmaceuticals
3:35 p.m. 鈥� 4:10 p.m.
Novel Inhibitors of Tryptophan Metabolism as Cancer Immunotherapies
Sarah Trewick, PhD, Senior Research Scientist - IOmet Pharma
4:10 p.m. 鈥� 4:45 p.m.
Immuno-Oncological Platforms for Preclinical Drug Development
Eva Oswald, PhD, Laboratory Head, Cellular Science - Oncotest, a Charles River company
4:45 p.m. 鈥� 5:00 p.m. Closing Remarks
Julia Schueler, Head of In Vivo Operations - Oncotest, a Charles River company
5:00 p.m. 鈥� 6:00 p.m. Networking Reception
10:00 a.m. 鈥� 11:00 a.m.
Registration & Brunch
11:00 a.m. 鈥� 11:15 a.m.
Welcome Remarks
Julia Schueler, Head of In Vivo Operations - Oncotest, a Charles River company
11:15 a.m. 鈥� 12:00 p.m. Keynote Speaker
Advanced Image Analysis and Mathematical Modeling to Explore Spatial Patterns of the Inflammatory Tumor Microenvironment
Friedrich Feuerhake, MD, Associate Professor of Neuropathology, Attending Neuropathologist, Head of Digital Pathology Group - Hanover Medical School
12:00 noon 鈥� 12:35 p.m.
TLR9 Agonists for the Immunotherapy of Cancer
Manuel Schmidt, PhD, Director of Translational Research, Oncology & Immunotherapy - Mologen
12:35 p.m. 鈥� 12:55 p.m. Break
12:55 p.m. 鈥� 1:30 p.m.
Multi-Pronged Attack on Cancer by Stimulation of the Innate Immune Receptor RIG-I Leads to Systemic Anti-Tumor Immunity
Marcel Renn, PhD, Project Leader, Biology - Rigontec
1:30 p.m. 鈥� 2:05 p.m.
Catarina Brito, PhD, Research Associate, Head of BioAssay Development Laboratory - ITQB-UNL
2:05 p.m. - 2:40 p.m.
Tools for the Next Generation of Immunotherapy
Olaf Hardt, PhD, Senior Project Manager - Miltenyi Biotec
2:40 p.m. 鈥� 3:00 p.m. Break
3:00 p.m. 鈥� 3:35 p.m.
Costimulatory T-cell Engagement with the CD137/HER2 Bispecific PRS-343 Demonstrates that Safe and Efficient Targeting of Costimulatory Receptors Requires Bispecifics
Marlon Hinner, PhD Director, Immuno-Oncology - Pieris Pharmaceuticals
3:35 p.m. 鈥� 4:10 p.m.
Novel Inhibitors of Tryptophan Metabolism as Cancer Immunotherapies
Sarah Trewick, PhD, Senior Research Scientist - IOmet Pharma
4:10 p.m. 鈥� 4:45 p.m.
Immuno-Oncological Platforms for Preclinical Drug Development
Eva Oswald, PhD, Laboratory Head, Cellular Science - Oncotest, a Charles River company
4:45 p.m. 鈥� 5:00 p.m. Closing Remarks
Julia Schueler, Head of In Vivo Operations - Oncotest, a Charles River company
5:00 p.m. 鈥� 6:00 p.m. Networking Reception
